Effectiveness of Parkinson´s Disease Multimodal Complex Treatment considering treatment duration and patient satisfaction

Effectiveness of Parkinson´s Disease Multimodal Complex Treatment considering treatment duration and patient satisfaction - Parkinson_complex

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00025225

Enrollment

120

Registered

2021-06-30

Start date

2021-07-07

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PARKINSON Multimodal Complex Treatment Non-Adherence G20.0 G20.1 G20.2 G20.9

Interventions

Group 1: Multimodal complex treatment according to OPS 8-97d.0 (7-13 days) Group 2: Multimodal complex treatment according to OPS 8-97d.1 (14-20 days)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with idiopathic Parkinson´s disease (according to the MDS-criteria) who were admitted to the Parkinson´s disease multimodal complex treatment.

Exclusion criteria

Exclusion criteria: inability to provide informed consent to participate in the study; acute psychotic symptoms; inability to complete a questionnaire, severe dementia.

Design outcomes

Primary

Measure	Time frame
Change in motor function assessed with the MDS-UPDRS II in the medication ON-state six months after discharge from Parkinson´s disease multimodal complex treatment (OPS 8-97d.0, OPS 8-97d.1).	—

Secondary

Measure	Time frame
Change in health-related quality of life (PDQ-8) after six months; impact of the treatment duration on changes in MDS-UPDRS II and PDQ-8; patient satisfaction or dissatisfaction with the treatment	—

Countries

Germany

Contacts

Public ContactKonstantin Heimrich

Department of Neurology, Jena University Hospital

konstantin.heimrich@med.uni-jena.de+49 3641 9 323493

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 5, 2026